Navigation Links
VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter

1st quarter revenues grow by 31% and gross profit increases 85%

ROCHESTER, N.Y., May 5 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that revenues for the first quarter of 2009 were over $2.1 million, a 31% increase over prior year's first quarter. The gross profit for the first quarter of 2009 was $1,119,786 compared to $604,119 in the first quarter of 2008, representing an 85% increase. Gross margin increased to 52%, in the first quarter ended March 31, 2009 compared to 37% in the first quarter of 2008, a 41% improvement. The Company's operating loss for the quarter ended March 31, 2009 was reduced by $591,243, or 62%, to $360,412 compared to a loss of $951,655 in the prior year's comparable period. Additionally, recent accounting pronouncements require the Company to reflect the changes in fair value of certain outstanding warrants. As a result, a non-cash, marked to market adjustment of $397,409 was recorded in the first quarter of 2009. Subsequent changes in fair values will be similarly reflected and included in the net income or loss for the reported period.

"The first quarter was extremely strong for VirtualScopics," stated Jeff Markin, president and chief executive officer of VirtualScopics. "We are especially encouraged in today's challenging economic environment that we have delivered greater than 80% growth in our project balance and 30% growth in revenue so far in 2009." He added, "Operationally we are seeing the benefits of this growth, along with our focus on systems and processes, which has yielded a 52% gross margin in the first quarter." He concluded, "Our first quarter top line and bottom line performance continues to demonstrate the increasing value we are providing to our customers and stockholders."

"The first quarter of 2009 represents the first quarter in the company's history where we generated cash from our operations(1)," said Molly Henderson, chief business and financial officer of VirtualScopics, Inc. She continued, "During the first quarter, the number of projects we performed services for increased 46% compared to the first quarter of 2008. Additionally, over 55% of our project work was in Phase II/III studies during the first quarter, compared to 27% a year ago. This greater demand, along with our processes that were built to efficiently scale the business, has allowed us to deliver solid results to start the year." She concluded, "We are very pleased with our financial performance for the first quarter and remain optimistic on our outlook for 2009."

Jeff Markin and Molly Henderson will provide a business update and discuss these results during the conference call on Wednesday, May 6, 2009 at 11:00 a.m. EDT. Interested participants should call 877-407-8031 when calling within the United States or 201-689-8031 when calling internationally. There will be a playback available until June 7, 2009. To listen to the playback, please call 877-660-6853 when calling within the United States or 201-612-7415 when calling internationally. For the replay, please use account number: 286, conference ID number: 320761.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

(1) Cash from operations = operating loss plus non-cash items (depreciation, amortization and stock compensation expense)

                       VirtualScopics, Inc. and Subsidiary
                 Condensed Consolidated Statements of Operations

                                                  For the Three Months Ended
                                                            March 31,
                                                       2009         2008

       Revenues                                     $2,134,370   $1,634,103
       Cost of services                              1,014,584    1,029,984
             Gross profit                            1,119,786      604,119
             Gross margin                                   52%          37%

       Operating expenses
         Research and development                      235,555      251,829
         Sales and marketing                           282,454      288,874
         General and administrative                    559,347      494,441
         Stock-based compensation expense              285,332      403,063
         Depreciation and amortization                 117,510      117,567
             Total operating expenses                1,480,198    1,555,774
       Operating loss                                 (360,412)    (951,655)

       Other income (expense)
         Interest income                                 3,193       28,725
         Other expense                                  (1,485)      (1,583)
         Loss on derivative financial instruments     (397,409)           -
       Total other income                             (395,701)      27,142
         Net Loss                                     (756,113)    (924,513)

       Series B preferred stock cash dividend           84,520       85,240
       Net loss attributable to
        common stockholders                          $(840,633) $(1,009,753)

       Basic and diluted net loss
        per common share                                $(0.04)      $(0.04)

       Weighted average number of
        common shares outstanding
        basic and diluted                           23,533,785   23,246,067

                      VirtualScopics, Inc. and Subsidiary
                     Condensed Consolidated Balance Sheets

                                                     March 31,  December 31,
                                                       2009         2008
                   Assets                           (unaudited)

    Current assets
     Cash and cash equivalents                      $3,137,405   $3,143,904
     Accounts receivable                             1,189,828    1,021,110
     Prepaid expenses and other current
      assets                                           306,792      263,297
     Total current assets                            4,634,025    4,428,311
    Patents, net                                     1,898,431    1,920,446
    Property and equipment, net                        368,079      355,479
    Other assets                                       125,905      156,788
     Total assets                                   $7,026,440   $6,861,024

       Liabilities and Stockholders' Equity

    Current liabilities
     Accounts payable and accrued expenses            $691,412     $659,009
     Accrued payroll                                   310,104      554,425
     Unearned revenue                                  740,557      291,594
       Derivative liability                            820,317            -
     Total current liabilities                       2,562,390    1,505,028

    Stockholders' Equity
    Convertible preferred stock, $0.001 par
     value; 15,000,000 shares authorized;
     8,400 shares designated Series A; issued
     and outstanding: 3,816 at March 31, 2009,
     3,976 at December 31, 2008; liquidation
     preference $1,000 per share                             4            4
    6,000 shares designated Series B;  issued
     and outstanding: 4,226 at March 31, 2009
     and December 31, 2008; liquidation preference
     $1,000 per share                                        4            4
    Common Stock, $0.001 par value; 85,000,000
     shares authorized; issued and outstanding,
     23,723,342 at March 31, 2009 and
     23,502,352 at December 31, 2008                    23,724       23,503
    Additional paid-in capital                      13,694,405   16,546,550
    Accumulated deficit                             (9,254,087) (11,214,065)
     Total stockholders' equity                      4,464,050    5,355,996
     Total liabilities and stockholders'
      equity                                        $7,026,440   $6,861,024

    CONTACT:      Company Contact:
                  Molly Henderson
                  Chief Business and Financial Officer
                  500 Linden Oaks
                  Rochester, New York 14625

SOURCE Virtual Scopics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Announces $4.35 Million Private Placement
2. VirtualScopics Backlog Exceeds a Record $20 Million
3. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
4. VirtualScopics Reports Second Quarter 2008 Results
5. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
6. VirtualScopics to Present at Two Upcoming Investor Conferences
7. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
8. VirtualScopics Backlog Rises to a Record $27 Million
9. VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
10. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
11. VirtualScopics Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology: